CoChat

Integrin Inhibitors Reaching the Clinic

Open access
Stupp, Roger, Ruegg, Curzio · 2007 · Journal of Clinical Oncology
Cited by 122

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Malignant cellular transformation is largely viewed as the consequence of autonomous cell genetic alterations, leading to the activation of oncogenes and the inactivation of tumor suppression genes and increasing genomic instability, which gives rise to a cell capable of limitless proliferation and survival, invasion, and metastasis. In addition, the formation of a tumor-associated vasculature—a process also referred to as tumor angiogenesis—has been recognized as an essential event promoting tumor progression. In the absence of tumor angiogenesis, tumors enter a state of dormancy, characterized by a balance between cell proliferation and apoptosis. During the last decade, significant advances have been made in the understanding of the tissue, cellular, and molecular events that regulate and mediate tumor angiogenesis. Many extracellular, cell surface, and intracellular molecules modulating angiogenesis have been identified and characterized, including growth factors and growth factor receptors, such as vascular endothelial growth factor (VEGF) and VEGF receptors; integrin and cadherin adhesion molecules; remodeling and guidance molecules and their receptors (eg, ephrin/Eph, angiopoietins/tyrosine kinase with Ig and EGF homology domains [Tie-2]); matrix-degrading enzymes (eg, matrix metalloproteinase [MMP] -9), signaling molecules, and transcription factors (eg, hypoxia inducible factor 1 alpha [HIF1 ]). Many of these molecules, in particular VEGF, have been or are being evaluated as novel therapeutic targets. Most recently, vascular integrin inhibition is being tested as antiangiogenic therapy. Integrins are heterodimer transmembrane receptors for the extracellular matrix composed of an alpha and beta subunit. Natural integrin ligands include laminin, fibronectin, and vitronectin, but they also include fibrinogen and fibrin, thrombospondin, MMP-2, and fibroblast growth factor 2. Integrins bind ligands by recognizing short amino acid stretches on exposed loops, particularly the arginine-glycine-aspartic acid (RGD) sequence. On ligation, integrins mediate complex signaling events, alone or in combination with growth factor receptors, regulating cell adhesion, proliferation, survival, and migration by activating canonical pathways, such as integrin-linked kinase (ILK), protein kinase B (PKB/Akt), mitogen-activated protein kinase (MAPK), Rac or nuclear factor kappa B (NFB). In resting vessels, integrins interact with the basal membrane, thereby maintaining vascular quiescence. During angiogenesis, they are essential for endothelial cell migration, proliferation, and survival. In preclinical studies, pharmacologic inhibition of integrin function efficiently suppressed angiogenesis and inhibited tumor progression. Of the 24 known integrin heterodimers, V 3 and V 5 were the first vascular integrins targeted to suppress tumor angiogenesis. These encouraging preclinical results stimulated researchers and industry to develop pharmacologic inhibitors of integrin function for clinical testing. Three classes of integrin inhibitors are currently in preclinical and clinical development: monoclonal antibodies targeting the extracellular domain of the heterodimer (eg, Vitaxin; MedImmune, Gaithersburg, MD), synthetic peptides containing an RGD sequence (eg, cilengitide; Merck KGaA, Darmstadt, Germany), and peptidomimetics (eg, S247; Pfizer, St Louis, MO), which are orally bioavailable nonpeptidic molecules mimicking the RGD sequence. In this issue of the Journal of Clinical Oncology, Nabors et al, on behalf of the New Approaches to Brain Tumor Therapy consortium, report on a phase I trial of cilengitide conducted in patients with recurrent glioma. Cilengitide (EMD 121974) is a cyclic RGD-motif containing peptide binding with high specificity to the V 3 and V 5 receptors. Glioblastoma, a highly vascularized and invasive tumor with microvascular proliferation as one of its hallmarks, is a logical target for such therapy. Overexpression of V 3 and V 5 has been shown in a majority of glioblastoma. In this trial, cilengitide was administered intravenously twice weekly at increasing doses up to 2,400 mg/m, without reaching dose-limiting toxicity. Overall tolerance was excellent, with occasional patients experiencing joint and bone pain. Thrombosis, thrombocytopenia, electrolyte imbalance, and anorexia were also reported. In five of the 51 patients, an objective response was observed. Sixteen other patients are reported as stable for a median duration of 5 months (range, 3 to 11 months). The pharmacokinetic profile was as reported previously, with no influence of comedications, in particular the frequent administration of enzymeinducing antiepileptic drugs. These results are intriguing for several reasons. First, despite a wide range of dosages, no clear pattern of toxicity could be determined. The absence of bleeding episodes is reassuring, as hemorrhage might have been expected with such a therapy and in this tumor type in parti

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.09.8376

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 122

Metadata

Authors
Stupp, R., & Ruegg, C.
Venue
Journal of Clinical Oncology
Published
2007-05-01
Volume
25
Issue
13
Pages
1637-1638
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2138986195
Cited by
122
References
1
FWCI
9.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrin Inhibitors Reaching the Clinic. https://app.cochat.ai/papers/10.1200/jco.2006.09.8376
The paper
Stupp, R., & Ruegg, C. (2007). Integrin Inhibitors Reaching the Clinic. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.09.8376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.